Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

| More on:
Woman in celebratory fist move looking at phone

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes.

Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:

Electro Optic Systems Holdings Ltd (ASX: EOS)

According to a note out of Bell Potter, its analysts have retained their buy rating on this defence and space company's shares with a trimmed price target of $2.20. The broker believes that the company's equity raise and investment in long lead time critical supplies is a prudent decision from management. It also feels it is reflective of its strengthened financial position and improved visibility over near-term sales opportunities. The Electro Optic Systems share price is trading at $1.59 on Friday afternoon.

Mesoblast Ltd (ASX: MSB)

Another note out of Bell Potter reveals that its analysts have retained their speculative buy rating on this biotechnology company's shares with a significantly improved price target of $1.40 (from 58 cents previously). Bell Potter notes that the FDA has used carefully chosen words to inform Mesoblast that the available clinical data from its Phase 3 study MSB-GvHD001 in children with steroid refractory acute graft versus host disease (SR a GvHD) appears sufficient to support a resubmission of the Biological Licence Application (BLA) for Remestemcel. It points out that the timing of the correspondence coincides with refreshed leadership at the newly formed Office of Therapeutic Products at the FDA. In light of this, the broker has renewed confidence for a prospective approval for Remestemcel later this year. It feels that a first approval may represent a gateway to a series of label expansions in the ensuing period. The Mesoblast share price is fetching 86.7 cents on Friday.

Suncorp Group Ltd (ASX: SUN)

Analysts at Morgan Stanley have retained their overweight rating and $17.05 price target on this insurance giant's shares. This follows news that the company has signed an agreement to sell its New Zealand life insurance business to Resolution Life for approximately $375 million. The broker feels the selling price is fair and expects it to result in a simplified business structure. Combined with the Suncorp Bank sale to ANZ Group Holdings Ltd (ASX: ANZ), it believes there could be some big capital returns to come in the near future. The Suncorp share price is on course to end the week at $16.25.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Electro Optic Systems. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

a man peers through a broken brick wall to see grey clouds gathering beyond it
Share Market News

Why this smashed ASX 200 share is a fundie's top value pick

It's an ASX consumer discretionary stock that has lost 40% of its value over the past year.

Read more »

Happy man working on his laptop.
Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Resources Shares

Up 51% from their 52-week low, is it too late to buy Mineral Resources shares?

Mineral Resources has been on a tear since mid-January. Do these top brokers think it's too late to buy?

Read more »

A laughing woman pushes her friend, who has her arms outstretched, in a supermarket trolley.
Retail Shares

Goldman says these 6 ASX retail shares are a buying opportunity

The latest retail trading data was historically weak, according to the Australian Bureau of Statistics.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Buy, hold or sell these 3 ASX 200 healthcare shares: Experts

These experts reveal their calls on CSL, Resmed and Sonic Healthcare shares today.

Read more »

A smiling boy holds a toy plane aloft while a girl watches on from a car near an airport runway.
Broker Notes

Buy one, sell the other: Goldman's verdict on these 2 ASX 200 travel shares

The broker says one of these stocks could deliver 30% share price growth in just one year.

Read more »

A couple in a supermarket laugh as they discuss which fruits and vegetables to buy
Broker Notes

Why Goldman Sachs just upgraded Coles shares

The broker has become a lot more positive on this supermarket giant.

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Financial Shares

What this top broker is saying about IAG shares

IAG shares are trading close to their four-year highs.

Read more »